『Dyslipidemia treatment “Duoroban Tablet” launched』

 

KyungDong Pharm Co., Ltd. will launch “Duoroban Tablet 10/5mg, 10/10mg”, a treatment for dyslipidemia, in May.

“Duorovan Tablet” is a combination of Ezetimibe and Rosuvastatin with different mechanisms, and is a product that shows a strong LDL-C lowering effect by blocking the absorption and production of cholesterol in the liver and small intestine.

“Duoroban Tablet” is safer than high-dose statins in terms of adverse reactions, and is highly effective in improving serum lipids in patients with diabetes.

As a combination drug, medication compliance has improved, and the launch of “Duoroban Tablet” by KyungDong Pharm Co., Ltd., which is convenient to take due to its small tablet size, is expected to be helpful in the treatment of patients with dyslipidemia.

   

♤Product Information♤

 

◈Product name: Duorovan Tab.

◈Ingredients/Content:

10/5mg - ezetimibe 10mg/rosuvastatin calcium 5.2mg in 1 tablet (5mg as rosuvastatin)

10/10mg - ezetimibe 10mg/rosuvastatin calcium 10.4mg in 1 tablet (10mg as rosuvastatin)

◈Efficacy/Effectiveness: Primary hypercholesterolemia

◈Usage/Dosage: This drug is administered once a day regardless of meals.

The dosage range of this drug is 10/5mg to 10/20mg per day. The recommended initial dose is 10/5 mg per day. For patients who require greater LDL-cholesterol reduction, the dose can be adjusted. After starting this drug or titrating the dose, check the blood lipid level at intervals of 4 weeks or more and adjust the dose accordingly. The dose can be increased up to 10/20 mg per day.

(Please refer to the product manual for detailed Dosage and Administration.)

◈Packing unit: 30 tablets

◈Product code: 10/5mg-648103740, 10/10mg-648103750

※ Please refer to the product manual for other details such as precautions for use.